116 related articles for article (PubMed ID: 29779347)
21. Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience.
Herishanu Y; Tadmor T; Braester A; Bairey O; Aviv A; Rahimi-Levene N; Fineman R; Levi I; Yuklea M; Ruchlemer R; Shvidel L; Polliack A
Hematol Oncol; 2019 Apr; 37(2):185-192. PubMed ID: 30756414
[TBL] [Abstract][Full Text] [Related]
22. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Vazquez ER; Spigel DR; Raefsky E; Bearden JD; Saez RA; Greco FA
Cancer; 2008 Mar; 112(6):1288-95. PubMed ID: 18189296
[TBL] [Abstract][Full Text] [Related]
23. Rituximab, fludarabine, and cyclophosphamide versus fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia: A systematic review with meta-analysis.
Nunes AA; da Silva AS; Souza KM; Koury Cde N; de Mello LM
Crit Rev Oncol Hematol; 2015 Jun; 94(3):261-9. PubMed ID: 25797826
[TBL] [Abstract][Full Text] [Related]
24. Oral fludarabine and rituximab as initial therapy for chronic lymphocytic leukemia or small lymphocytic lymphoma: population-based experience matches clinical trials.
Gerrie AS; Toze CL; Ramadan KM; Li CH; Sutherland J; Yee A; Connors JM
Leuk Lymphoma; 2012 Jan; 53(1):77-82. PubMed ID: 21756026
[TBL] [Abstract][Full Text] [Related]
25. Rituximab, fludarabine, and total body irradiation as conditioning regimen before allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukemia: long-term prospective multicenter study.
Michallet M; Socié G; Mohty M; Sobh M; Bay JO; Morisset S; Labussière-Wallet H; Tabrizi R; Milpied N; Bordigoni P; El-Cheikh J; Blaise D
Exp Hematol; 2013 Feb; 41(2):127-33. PubMed ID: 23089183
[TBL] [Abstract][Full Text] [Related]
26. [Efficacy of chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia].
Fang C; Xu W; Xu M; Hong M; Zhu DX; Zhu HY; Wu YJ; Fan L; Qiao C; Zhuang Y; Miao KR; Liu P; Li JY
Zhonghua Xue Ye Xue Za Zhi; 2011 Jan; 32(1):3-7. PubMed ID: 21429392
[TBL] [Abstract][Full Text] [Related]
27. Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group.
Kovacs G; Robrecht S; Fink AM; Bahlo J; Cramer P; von Tresckow J; Maurer C; Langerbeins P; Fingerle-Rowson G; Ritgen M; Kneba M; Döhner H; Stilgenbauer S; Klapper W; Wendtner CM; Fischer K; Hallek M; Eichhorst B; Böttcher S
J Clin Oncol; 2016 Nov; 34(31):3758-3765. PubMed ID: 27573660
[TBL] [Abstract][Full Text] [Related]
28. [Economic evaluation of rituximab added to fludarabine plus cyclophosphamide versus fludarabine plus cyclophosphamide for the treatment of chronic lymphocytic leukemia].
Casado LF; García Marco JA; Gilsanz F; González M; Ríos E; de la Serna J; Urbano A; Vicente V; Rubio-Terrés C; Castro AJ
Gac Sanit; 2011; 25(4):274-81. PubMed ID: 21664727
[TBL] [Abstract][Full Text] [Related]
29. A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL.
Jain N; Balakrishnan K; Ferrajoli A; O'Brien SM; Burger JA; Kadia TM; Cortes JE; Ayres ML; Tambaro FP; Keating MJ; Gandhi V; Wierda WG
Oncotarget; 2017 Mar; 8(13):22104-22112. PubMed ID: 27655665
[TBL] [Abstract][Full Text] [Related]
30. [Curative efficacy of fludarabine combined with rituximab and amifostine on aged patient with B-chronic lymphocytic leukemia].
Liu Y; Zhu HL; Lu XC; Li SX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Oct; 15(5):989-92. PubMed ID: 17956676
[TBL] [Abstract][Full Text] [Related]
31. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.
Robak T; Dmoszynska A; Solal-Céligny P; Warzocha K; Loscertales J; Catalano J; Afanasiev BV; Larratt L; Geisler CH; Montillo M; Zyuzgin I; Ganly PS; Dartigeas C; Rosta A; Maurer J; Mendila M; Saville MW; Valente N; Wenger MK; Moiseev SI
J Clin Oncol; 2010 Apr; 28(10):1756-65. PubMed ID: 20194844
[TBL] [Abstract][Full Text] [Related]
32. Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice.
Zaja F; Mian M; Volpetti S; Visco C; Sissa C; Nichele I; Castelli M; Ambrosetti A; Puglisi S; Fanin R; Cortelazzo S; Pizzolo G; Trentin L; Rodeghiero F; Paolini R; Vivaldi P; Sancetta R; Isola M; Semenzato G
Am J Hematol; 2013 Nov; 88(11):955-60. PubMed ID: 23861234
[TBL] [Abstract][Full Text] [Related]
33. Emerging information on the use of rituximab in chronic lymphocytic leukemia.
Keating MJ; O'Brien S; Albitar M
Semin Oncol; 2002 Feb; 29(1 Suppl 2):70-4. PubMed ID: 11842391
[TBL] [Abstract][Full Text] [Related]
34. Advancing therapy for chronic lymphocytic leukemia--the role of rituximab.
Hillmen P
Semin Oncol; 2004 Feb; 31(1 Suppl 2):22-6. PubMed ID: 15042531
[TBL] [Abstract][Full Text] [Related]
35. Chronic lymphocytic leukemia: current and emerging treatment approaches.
Kay NE; Rai KR; O'Brien S
Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 22):1-10; quiz 11-2. PubMed ID: 17143256
[TBL] [Abstract][Full Text] [Related]
36. NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment.
Bo MD; Del Principe MI; Pozzo F; Ragusa D; Bulian P; Rossi D; Capelli G; Rossi FM; Niscola P; Buccisano F; Bomben R; Zucchetto A; Maurillo L; de Fabritiis P; Amadori S; Gaidano G; Gattei V; Del Poeta G
Ann Hematol; 2014 Oct; 93(10):1765-74. PubMed ID: 24923451
[TBL] [Abstract][Full Text] [Related]
37. [Clinical Efficacy and Safety of Rituximab Combined with Fludarabine and Cyclophosphamide for Treatment of Chronic Lymphocytic Leukemia].
Han HJ; Lu YW; Xia RX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):25-9. PubMed ID: 26913388
[TBL] [Abstract][Full Text] [Related]
38. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia.
Tsimberidou AM; Kantarjian HM; Cortes J; Thomas DA; Faderl S; Garcia-Manero G; Verstovsek S; Ferrajoli A; Wierda W; Alvarado Y; O'Brien SM; Albitar M; Keating MJ; Giles FJ
Cancer; 2003 Apr; 97(7):1711-20. PubMed ID: 12655528
[TBL] [Abstract][Full Text] [Related]
39. Chemoimmunotherapy with oral low-dose fludarabine, cyclophosphamide and rituximab (old-FCR) as treatment for elderly patients with chronic lymphocytic leukaemia.
Gozzetti A; Candi V; Fabbri A; Schiattone L; Cencini E; Lauria F; Frasconi A; Crupi R; Raspadori D; Papini G; Defina M; Bartalucci G; Bocchia M
Leuk Res; 2014 Aug; 38(8):891-5. PubMed ID: 24934847
[TBL] [Abstract][Full Text] [Related]
40. [Survival analysis of 118 chronic lymphocytic leukemia patients with abnormal TP53 gene in the era of traditional immunochemotherapy].
Li XT; Zhu HY; Wang L; Xia Y; Liang JH; Wu JZ; Wu W; Cao L; Fan L; Xu W; Li JY
Zhonghua Xue Ye Xue Za Zhi; 2019 May; 40(5):378-383. PubMed ID: 31207701
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
